argenex’s (ARGX) “Neutral” Rating Reiterated at Robert W. Baird

Robert W. Baird reissued their neutral rating on shares of argenex (NASDAQ:ARGX) in a report released on Thursday morning, Marketbeat.com reports. They currently have a $858.00 price objective on the stock, down from their previous price objective of $924.00.

A number of other research analysts have also recently issued reports on the company. Royal Bank Of Canada boosted their target price on argenex from $860.00 to $925.00 and gave the company an “outperform” rating in a research note on Wednesday. Wedbush increased their target price on argenex from $880.00 to $1,000.00 and gave the stock an “outperform” rating in a research note on Friday, November 14th. Truist Financial lifted their price target on shares of argenex from $700.00 to $918.00 and gave the company a “buy” rating in a research note on Monday, September 15th. Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a research report on Wednesday, October 8th. Finally, Evercore ISI raised their price objective on shares of argenex from $775.00 to $910.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. Nineteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $982.33.

argenex Stock Performance

Shares of ARGX stock opened at $854.99 on Thursday. argenex has a one year low of $510.05 and a one year high of $934.62. The company has a 50 day moving average price of $868.88 and a 200 day moving average price of $726.82. The firm has a market capitalization of $52.64 billion, a price-to-earnings ratio of 36.71, a price-to-earnings-growth ratio of 0.86 and a beta of 0.37.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, October 30th. The company reported $4.40 EPS for the quarter, topping the consensus estimate of $4.37 by $0.03. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.07 billion. argenex had a return on equity of 29.78% and a net margin of 41.58%. As a group, equities analysts forecast that argenex will post 3.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ARGX. Sound View Wealth Advisors Group LLC grew its position in argenex by 3.4% during the 3rd quarter. Sound View Wealth Advisors Group LLC now owns 396 shares of the company’s stock worth $292,000 after acquiring an additional 13 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of argenex by 6.8% in the 3rd quarter. GAMMA Investing LLC now owns 251 shares of the company’s stock worth $185,000 after acquiring an additional 16 shares in the last quarter. Portside Wealth Group LLC lifted its position in argenex by 2.8% during the 3rd quarter. Portside Wealth Group LLC now owns 583 shares of the company’s stock valued at $430,000 after acquiring an additional 16 shares during the period. Cromwell Holdings LLC boosted its stake in argenex by 10.0% during the third quarter. Cromwell Holdings LLC now owns 187 shares of the company’s stock worth $138,000 after acquiring an additional 17 shares in the last quarter. Finally, Wealth Alliance LLC grew its holdings in argenex by 2.7% in the third quarter. Wealth Alliance LLC now owns 839 shares of the company’s stock worth $619,000 after purchasing an additional 22 shares during the period. Institutional investors own 60.32% of the company’s stock.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.